title: The Suppression of Wound Healing Response with Sirolimus and Sunitinib Following Experimental Trabeculectomy in a Rabbit Model.
abstract: OBJECTIVE
  To investigate the effects of sirolimus and sunitinib on wound healing in experimental glaucoma filtering surgery (GFS).
  
  
  METHODS
  Thirty-five male New Zealand pigmented rabbits were randomly assigned to five groups, each including seven rabbits: The rabbits in the control group were not operated on and did not receive any treatment. The rabbits in the sham group underwent trabeculectomy and had one drop of saline instilled four times a day for 14 days. The rabbits in the mitomycin-C (MMC) group underwent trabeculectomy, and a sponge soaked in 0.4 mg/mL MMC was applied intraoperatively to the scleral surgical site for three minutes. The rabbits in the sirolimus group underwent trabeculectomy and 30 ng/mL sirolimus-soaked sponge was applied intraoperatively to the scleral surgical site for three minutes. Sunitinib 0.5 mg/mL four drops in a day were applied in the sunitinib group for 14 days after surgery. On day 14 of the experiment, eyes were enucleated and histologically and immunohistochemically analyzed. Statistical analyses of the study were performed with Kruskal-Wallis variance analysis and Mann-Whitney U test.
  
  
  RESULTS
  The mean fibroblast and MNC numbers and the mean immunostaining intensities of transforming growth factor-β (TGF-β), fibroblast growth factor-β (FGF-β) and platelet derived growth factor (PDGF) in the MMC, sirolimus and sunitinib groups were statistically significantly lower than those of the sham group (p < 0.01). The mean fibroblast and MNC numbers and the mean immunostaining intensities of TGF-β, FGF-β and PDGF in the MMC, sirolimus and sunitinib groups were similar (p > 0.05).
  
  
  CONCLUSIONS
  Our study suggests that the applications of sirolimus and sunitinib effectively suppress the subconjunctival scarring after experimental GFS.
authors.affiliation: a Department of Ophthalmology , Firat University, School of Medicine , Elazig , Turkey and.
authors.forename: Kenan
authors.initials: K
authors.lastname: Eren
authors.affiliation: a Department of Ophthalmology , Firat University, School of Medicine , Elazig , Turkey and.
authors.forename: Burak
authors.initials: B
authors.lastname: Turgut
authors.affiliation: b Department of Pathology , Firat University, School of Medicine , Elazig , Turkey.
authors.forename: Mehmet Mustafa
authors.initials: MM
authors.lastname: Akin
authors.affiliation: a Department of Ophthalmology , Firat University, School of Medicine , Elazig , Turkey and.
authors.forename: Tamer
authors.initials: T
authors.lastname: Demir
mesh_terms: D000477:Alkylating Agents / Q000008:administration & dosage; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D016222:Fibroblast Growth Factor 2 / Q000378:metabolism; D005346:Fibroblast Growth Factors / Q000378:metabolism; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology*; D011817:Rabbits; D020123:Sirolimus / Q000494:pharmacology*; D000077210:Sunitinib; D014129:Trabecular Meshwork / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D014130:Trabeculectomy; D016212:Transforming Growth Factor beta / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D000477:Alkylating Agents; D020533:Angiogenesis Inhibitors; D007166:Immunosuppressive Agents; D007211:Indoles; D010982:Platelet-Derived Growth Factor; D011758:Pyrroles; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2; D016685:Mitomycin; D005346:Fibroblast Growth Factors; D000077210:Sunitinib; D020123:Sirolimus
keywords: Experimental; glaucoma; mitomycin-C; sirolimus; sunitinib; trabeculectomy